Centre for Drug Development: Strategy and portfolio

Our strategic priorities

Our ambition is to accelerate the delivery of the next generation of medicines to the patients who need them.

As the world's only charity-funded drug development facility, our strategy is uniquely focused by the drive for patient benefit. We are particularly interested in innovative projects, and our strengths are in:

  • First in class therapies
  • First in human clinical trials
  • Projects where we can use pharmacodynamic and stratification biomarker technologies to identify and progress new treatments which have the greatest potential for patient benefit

We maintain a broad portfolio across therapeutic modalities including antibodies, imaging agents, cell therapies, vaccines and targeted small molecules.

Our pipeline

PortfolioOur development portfolio contains 10 small molecule agents and 10 biologicals as of September 2017. Download the full pipeline or browse the agents below.

 

Agent

Target or technology

Partnerships

Indications

Status

SnMP

HO1

Kings College London

Solid, others tbc

Exploratory

STK-01

HPG-docetaxel

Sitka Biopharma

Bladder

Exploratory

BT1718

MT1-MMP

Bicycle Therapeutics

Solid, lung, sarcoma, breast

 Phase 1

LY3143921

Cdc7

Lilly

Solid, colorectal, ovarian

Phase 1

AZD3965

MCT1

AstraZeneca

Solid, prostate, non-Hodgkin lymphoma, B cell

Phase 1

AT13148

AGC, ROCK

Astex Pharmaceuticals

Solid

Completed phase 1

Vandetanib/ Selumetinib

EGFR, VEGFR, MEK

AstraZeneca

Solid, lung

 Completed phase 1

AT9283

Aurora Kinase

Astex Pharmaceuticals

Paediatric solid

Completed phase 1

mIBG

NAT nor-adrenalin transporter

The Royal Marsden NHS Foundation Trust

Neuroblastoma

Phase 2

AMG319

p110d PI3K

Amgen

Head and neck oropharyngeal

Phase 2

Agent

Target or technology

Partnerships

Indications

Status

Tb535H

5T4 / T-cell engaging antibody (tribody)

Biotecnol

Solid tumours; including thoracic / lung cancers

Due diligence

SCIB2

Vaccine
NY-ESO-1

Scancell

Solid, lung

Due diligence

MEDI3039

Recombinant protein
TrailR2

MedImmune

 

Solid, colorectal, NSCLC

 

Exploratory

 

ATN658

Antibody
uPAR

Monopar Therapeutics

 

Solid, colon, breast, lung, melanoma

 

Exploratory

 

AST-VAC2

Vaccine
LAMP, hTERT

Asterias Biotherapeutics

Lung

Trial set up

BI-1206

Antibody
CD32b, FcγRIIB

BioInvent, Bloodwise

Lymphoma, B cell, CLL

Phase 1

MOv18 

Antibody
α-folate R

King's College London

Solid

Phase 1

1RG CART

Cell therapy
GD2

Great Ormond Street Hospital for Children

Neuroblastoma

Phase 1

Dl-B4

Antibody
CD19

Merc Serono

Lymphoma, B cell, CLL

Completed phase 1

MVA-EBV1b

Vaccine
EBNA-LMP2

University of Birmingham

Nasopharyngeal, lymphoma

Completed phase 1

Portfolio news

First patient treated in AZD3965 expansion phase

July 2018
The expansion phase of AZD3965, a first in class phase 1 trial sponsored by our Centre for Drug Development and in partnership with AstraZeneca, has now opened. AZD3965 targets the monocarboxylate transporter 1 (MCT1), disrupting lactate transport and affecting cellular metabolism. The first patient from the selected patient population, the tumour type Diffuse Large B Cell Lymphoma, was dosed with the RP2D in May at Leicester Royal Infirmary, beginning the expansion phase which is due to be carried out in seven centres (including 6 ECMCs) across the UK.

Our track record of marketed drugs

Abiraterone

Discovered at the CRUK Cancer Therapeutics Unit at The Institute of Cancer Research, and developed by the Centre for Drug Development before licensing to Janssen Biotech, Abiraterone acetate (Zytiga®) is a hormonal therapy for prostate cancer.

Pemetrexed

Pemetrexed (Alimta®) is indicated for pleural mesothelioma and non-small cell lung cancer.
 
 

Temozolomide

One of our earliest successes, discovered by CRUK-funded scientists and developed by the CDD in the 1980s and 90s, Temozolomide (Temodal ®) is used worldwide as the frontline drug for glioblastoma and astrocytoma.

Etoposide phosphate

Etoposide phosphate (Etopophos®) is a drug used in small cell lung cancer and testicular tumours that no longer respond to other treatments.
 

Rucaparib

Discovered by CRUK scientists at the Northern Institute for Cancer Research in a programme built on breakthroughs from CRUK's basic science, we progressed the early development of the PARP inhibitor Rucaparib (Rubraca®).

Formestane

Formestane (Lentaron®) is a selective aromatase inhibitor that was indicated for the use in breast cancer, but was subsequently superseded by third-generation inhibitors such as letrozole.

Contact us

We are looking to partner with leading pharmaceutical and biotechnology companies and academic scientists who require resource, capabilities or expertise to develop new agents for the treatment of cancer.

Get in touch

Share this page